SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
209.9 EUR
+0.7 (+0.33%)
Overall 56S1 gets a fundamental rating of 5 out of 10. We evaluated 56S1 against 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year 56S1 was profitable.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 56S1 (3.35%) is comparable to the rest of the industry.
56S1's Return On Equity of 6.54% is in line compared to the rest of the industry. 56S1 outperforms 45.45% of its industry peers.
56S1 has a Return On Invested Capital of 5.94%. This is comparable to the rest of the industry: 56S1 outperforms 54.55% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.70%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a Profit Margin (8.96%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 68.18% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 45.64%, 56S1 perfoms like the industry average, outperforming 59.09% of the companies in the same industry.
In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
Compared to 5 years ago, 56S1 has more shares outstanding
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.49 indicates that 56S1 is not in any danger for bankruptcy at the moment.
56S1's Altman-Z score of 4.49 is fine compared to the rest of the industry. 56S1 outperforms 72.73% of its industry peers.
56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 50.00% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.49 |
ROIC/WACC0.63
WACC9.37%
2.3 Liquidity
A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 68.18% of the companies in the same industry.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1 has a Quick ratio of 0.50. This is in the lower half of the industry: 56S1 underperforms 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 4.19% on average per year.
Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 7.72% in the last year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
The Earnings Per Share is expected to grow by 22.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 10.12% on average per year.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 48.70, the valuation of 56S1 can be described as expensive.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 26.87, 56S1 is valued quite expensively.
The Price/Forward Earnings ratio is 39.09, which means the current valuation is very expensive for 56S1.
68.18% of the companies in the same industry are cheaper than 56S1, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.46, 56S1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.7 | ||
| Fwd PE | 39.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
56S1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.55 | ||
| EV/EBITDA | 28.1 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 56S1's earnings are expected to grow with 23.06% in the coming years.
PEG (NY)1.66
PEG (5Y)11.61
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.33%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is comparable with the industry average which is at 0.48.
Compared to an average S&P500 Dividend Yield of 1.94, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.41% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.41%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/2/2026, 7:00:00 PM)
209.9
+0.7 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.43B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target240.69 (14.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0.77%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.7 | ||
| Fwd PE | 39.09 | ||
| P/S | 6.93 | ||
| P/FCF | 54.55 | ||
| P/OCF | 27.96 | ||
| P/B | 5.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.1 |
EPS(TTM)4.31
EY2.05%
EPS(NY)5.37
Fwd EY2.56%
FCF(TTM)3.85
FCFY1.83%
OCF(TTM)7.51
OCFY3.58%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.66
PEG (5Y)11.61
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.49 |
F-Score8
WACC9.37%
ROIC/WACC0.63
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 48.7 and the Price/Book (PB) ratio is 5.06.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.